Search Results

The company is building a new facility in California, its third U.S.-based radioligand therapy production site, and expanding an Indianapolis site for producing isotopes for cancer treatment.

An increase in project orders drives further site growth

Five sites across the U.S. are now participating in the Phase 1b study

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”).

Microbot Medical Inc. announces that Brigham and Women’s Hospital, a leading academic medical center located in Boston, Massachusetts, will participate as a clinical trial site for the pivotal human clinical trial as part of its Investigational Device Exemption application for its LIBERTY® Endovascular Robotic Surgical System.

Vivos Therapeutics, Inc. today announced positive results from a 7-month, multi-site marketing pilot testing the core assumptions behind Vivos’ new affiliation and medical sleep specialist marketing and distribution model.

Eli Lilly and Company announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company’s total investment in this site from $3.7 billion to $9 billion.